PT-141 (Bremelanotide)_Dosage, benefits & legal status
Also known as bremelanotide, Vyleesi, PT141
An approved shot that boosts sexual desire through the brain.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is PT-141 (Bremelanotide)?
Plain language first. The technical label stays, but it never stands alone.Overview
It raises sexual desire through brain signaling rather than blood flow, which is different from how erection drugs work. It is FDA-approved for low libido in women.
What it's used for
An approved shot that boosts sexual desire and arousal by acting on the brain rather than blood flow. It is used for low libido in both women and men.
How does PT-141 (Bremelanotide) work?
What it does in the body, and where.PT-141 works on the brain rather than on blood flow, which makes it fundamentally different from the erectile-dysfunction drugs it gets compared to.
- 01It activates MC4R in the brainA melanocortin receptor involved in sexual desire, appetite, and arousal signaling.
- 02Desire rises, rather than blood flowDrugs like sildenafil act on blood vessels. This acts upstream of that, on the wanting rather than the mechanics.
- 03Approved for one specific groupFDA-approved as Vyleesi for low sexual desire in premenopausal women. Use in men is off-label and less studied.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Sexual desire in women
FDA-approved- RegulatoryApproved by the FDA in June 2019 for low sexual desire that causes distress in premenopausal women.
- Human trialTwo late-stage trials in more than 1,200 women showed improved desire and reduced distress against placebo, though the effect was modest.
- Human trialNausea affected 40% of users, particularly with the first injection. It required anti-nausea treatment in 13% and caused 8% to stop.
Sexual function in men
Investigational- Human trialIn men who did not respond to standard erection drugs, about 34% responded against 9% on placebo.
- No dataCompounded versions are not the approved product and have not been reviewed by the FDA.
The approved use is in women, and the male findings come from smaller off-label studies we could not link to a primary source.
The published record
Papers and trials about PT-141 (Bremelanotide)
Searched: PT-141, bremelanotide, Vyleesi, PT141.
91 papers tagged human · 38 not reviews or lab · 16 clinical trial publications
10 registered trials · 4 with posted results
Furthest stage reached: Approved in the US
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about PT-141 (Bremelanotide)
Evidence
FDA-approved
Category
Sexual and hormonal
Common vial
10 mg
Half-life
About 2.7 hours
How much, and do you cycle it?
The range, and whether you take breaks.1.75 mg per dose, as needed, before activity. Not cycled, but the label caps it: one dose in 24 hours, and no more than 8 in a month FDA label
Taken as needed rather than on a schedule, but the label sets a hard ceiling on frequency because of transient blood pressure rises and skin darkening with repeat dosing. That ceiling is the closest thing to a cycling rule here, and it is a real one.
About 2.7 hoursFDA label
Largely cleared from plasma within 12 hours, which is why the label sets a 24 hour minimum between doses.
Source: Vyleesi (bremelanotide) label section 12.3
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
PT-141 (Bremelanotide) starts at $19.24 across 164 vendors, typically $2.87 – $7.00 per mg.
216 listings, last read Oct 24, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Follow the label that came with it.
This is an approved product, and its own label sets how long it keeps once mixed. Those windows vary enormously between products, from use-immediately to about a month, so the label is the only thing worth following here. Vials of the same compound sold by peptide vendors arrive with no label and no established holding time.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 71% charged residues, 43% hydrophobic. Water usually sufficient.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- Uncontrolled high blood pressure
- Known cardiovascular disease
- Pregnancy
Stop and get help
- Chest pain or a severe headache with a racing heart
- An erection lasting more than four hours, which is a medical emergency
- Signs of an allergic reaction
Common effects
- Nausea, which is the most common effect
- A temporary rise in blood pressure and drop in heart rate
- Flushing and headache
- Darkening of skin or gums with repeated use
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is PT-141 (Bremelanotide) approved?
And where the numbers on this page come from.Yes. PT-141 (Bremelanotide) is FDA approved and available on prescription in the United States.
- Approval statusFDA-approved
- RouteUnder the skin (subcutaneous)
- Checked22 July 2026
- DoseFrom the drug label. The manufacturer tested this range and a regulator reviewed it.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
FDA-approved in June 2019 as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women. The label sets limits the research market does not: no more than one dose in 24 hours and no more than eight doses a month, both to limit blood pressure effects. It is contraindicated in uncontrolled high blood pressure or known cardiovascular disease, and the label states it is not indicated for postmenopausal women, for men, or to enhance sexual performance.
What regulators say
From official documentsEnforcement naming this compound
Vendor product named as an unapproved new drug (Royal Peptides, August 2026)
The vendor's product, not the approved Vyleesi This is a finding about one seller's vial, not about the compound or any approved product containing it.
Read the letter
You can compare this against the whole library, or read how to check a seller.
What else is like PT-141 (Bremelanotide)?
Others in Sexual and hormonal, side by side.If you're weighing PT-141 (Bremelanotide), it's worth reading Kisspeptin, Oxytocin, and HCG (Human Chorionic Gonadotropin) in the same class.
An approved shot that boosts sexual desire through the brain.
- Dose
- 1.75 mg per dose
- How often
- As needed, before activity
A peptide that switches on natural sex-hormone signaling for libido and fertility.
- Dose
- 0.1 up to 0.2 mg per dose
- How often
- Daily in vendor protocols
The bonding hormone, used for connection, mood, and sometimes libido.
- Dose
- 18 up to 40 IU per dose
- How often
- As needed
A hormone shot that keeps the testicles making testosterone and sperm.
- Dose
- 250 up to 500 IU per dose (alongside testosterone therapy)
- How often
- 2-3x per week
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
Sources
- FDA prescribing information, Vyleesi(2019)FDA approval for low sexual desire in premenopausal women.
Beyond these, 135 records are indexed. Browse the records